Profile data is unavailable for this security.
About the company
Becton, Dickinson and Company is a global medical technology company. The Company is engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, and others. The Company's BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a wide range of settings. The BD Medical segment consists of various business units, including medication delivery solutions, medication management solutions, and pharmaceutical systems. The Company's BD Life Sciences segment provides products for the collection and transport of diagnostics specimens, and instruments and reagent systems to detect a broad range of infectious diseases, healthcare-associated infections and cancers. The Company's BD Interventional segment provides vascular, urology, oncology and surgical specialty products.
- Revenue in USD (TTM)19.49bn
- Net income in USD1.27bn
- Incorporated1906
- Employees73.00k
- LocationBecton Dickinson and CoOne Becton DriveFRANKLIN LAKES 07417-1880United StatesUSA
- Phone+1 (201) 847-6800
- Websitehttps://www.bd.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GE HealthCare Technologies Inc | 19.55bn | 1.39bn | 38.77bn | 51.00k | 27.99 | 5.42 | 18.96 | 1.98 | 3.04 | 3.03 | 42.77 | 15.67 | 0.6518 | 5.65 | 4.44 | 383,372.60 | 5.39 | -- | 7.45 | -- | 40.52 | -- | 8.28 | -- | 0.8295 | 5.43 | 0.5636 | -- | 6.60 | -- | -26.82 | -- | -- | -- |
| DexCom Inc | 3.62bn | 541.50m | 51.77bn | 9.60k | 104.76 | 25.02 | 71.17 | 14.29 | 1.28 | 1.28 | 8.55 | 5.37 | 0.6215 | 3.04 | 4.29 | 377,322.90 | 9.29 | 8.30 | 13.11 | 10.50 | 63.65 | 65.90 | 14.95 | 14.14 | 2.48 | -- | 0.5465 | 0.00 | 24.49 | 28.56 | 58.70 | -- | 28.66 | -- |
| Edwards Lifesciences Corp | 6.00bn | 1.40bn | 52.04bn | 19.80k | 37.56 | 7.81 | 33.70 | 8.67 | 2.30 | 2.30 | 9.85 | 11.06 | 0.6802 | 1.35 | 8.47 | 303,272.70 | 15.85 | 16.63 | 18.21 | 19.12 | 77.02 | 76.71 | 23.30 | 24.84 | 2.40 | -- | 0.0816 | 0.00 | 11.56 | 10.03 | -7.85 | 13.70 | 1.96 | -- |
| Becton Dickinson and Co | 19.49bn | 1.27bn | 67.36bn | 73.00k | 53.21 | 2.66 | 18.99 | 3.46 | 4.38 | 4.23 | 67.25 | 87.68 | 0.3699 | 3.31 | 8.57 | 267,013.70 | 2.47 | 2.37 | 2.89 | 2.70 | 41.37 | 45.78 | 6.68 | 6.95 | 0.6435 | 6.45 | 0.3887 | 81.23 | 2.66 | 3.92 | -4.85 | 12.97 | -0.4737 | 3.94 |
| Boston Scientific Corporation | 14.24bn | 1.57bn | 99.10bn | 48.00k | 62.95 | 5.12 | 35.83 | 6.96 | 1.07 | 1.07 | 9.73 | 13.16 | 0.4213 | 1.99 | 6.78 | 296,666.70 | 4.71 | 2.50 | 5.43 | 2.91 | 69.65 | 68.84 | 11.18 | 6.47 | 0.8170 | 5.16 | 0.3179 | 0.00 | 12.29 | 7.71 | 144.55 | -0.4276 | 7.82 | -- |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Dec 2023 | 24.90m | 8.62% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 14.54m | 5.03% |
| SSgA Funds Management, Inc.as of 31 Dec 2023 | 12.92m | 4.47% |
| T. Rowe Price Associates, Inc. (Investment Management)as of 31 Dec 2023 | 9.91m | 3.43% |
| T. Rowe Price Investment Management, Inc.as of 31 Dec 2023 | 7.35m | 2.54% |
| Morgan Stanley Investment Management Ltd.as of 31 Dec 2023 | 6.87m | 2.38% |
| Wellington Management Co. LLPas of 31 Dec 2023 | 6.67m | 2.31% |
| Geode Capital Management LLCas of 31 Dec 2023 | 5.48m | 1.90% |
| Massachusetts Financial Services Co.as of 31 Dec 2023 | 4.03m | 1.40% |
| Managed Account Advisors LLCas of 31 Dec 2023 | 3.84m | 1.33% |
